Pharmafile Logo

vaccine reimbursement

- PMLiVE

Why the field is critical tonext-generation marketing

AI is fundamentally changing the way marketing operates omnichannel journeys, enabling true next-best communication

- PMLiVE

AstraZeneca reports positive phase 3 data for tozorakimab in COPD

COPD affects nearly 400 million people globally and is the third leading cause of death worldwide

- PMLiVE

AI-powered launches on a limited budget: a playbook for emerging biopharma

Every AI decision must drive better outcomes and add greater value for clients

Person on phone

The gap between hype and reality, what patients really say about weight loss drugs

Explore real patient conversations about weight loss drugs, uncovering challenges, support strategies, and the critical need for clear, reliable healthcare communication.

Cuttsy + Cuttsy

- PMLiVE

Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn

The acquisition will help Lilly to expand its capabilities in cell and gene therapy

- PMLiVE

MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment

SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK

- PMLiVE

Beyond the injection: why the real work of weight loss starts where the drug leaves off

Behaviour change is not primarily a matter of information or intention, but of habit, environment, identity and reward

- PMLiVE

J&J’s Icotyde approved by US FDA for plaque psoriasis

Plaque psoriasis affects over 125 million people worldwide

- PMLiVE

Envision appoints Darren Coleman as Executive VP, Chief Information Officer

Coleman previously held senior leadership positions at Syneos Health and AI One

- PMLiVE

AL-S Pharma release new data from AP-101 phase 2 trial for ALS

ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord

- PMLiVE

Envision appoints Jay Ferro as President, Technology and Chief Product Officer

Ferro was previously EVP, Chief Information, Technology & Product Officer at Clario

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links